Next Article in Journal
Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry
Next Article in Special Issue
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
Previous Article in Journal
Development of Novel Vaccines against Enterovirus-71
Previous Article in Special Issue
Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma
Article Menu

Export Article

Open AccessReview
Viruses 2016, 8(1), 4; doi:10.3390/v8010004

Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus

Department of Molecular Cell Biology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
Author to whom correspondence should be addressed.
Academic Editors: E. Antonio Chiocca and Martine L.M. Lamfers
Received: 11 September 2015 / Revised: 4 December 2015 / Accepted: 15 December 2015 / Published: 24 December 2015
(This article belongs to the Special Issue Oncolytic Viruses)
View Full-Text   |   Download PDF [684 KB, uploaded 24 December 2015]   |  


Reoviruses are non-enveloped viruses with a segmented double stranded RNA genome. In humans, they are not associated with serious disease. Human reoviruses exhibit an inherent preference to replicate in tumor cells, which makes them ideally suited for use in oncolytic virotherapies. Their use as anti-cancer agent has been evaluated in several clinical trials, which revealed that intra-tumoral and systemic delivery of reoviruses are well tolerated. Despite evidence of anti-tumor effects, the efficacy of reovirus in anti-cancer monotherapy needs to be further enhanced. The opportunity to treat both the primary tumor as well as metastases makes systemic delivery a preferred administration route. Several pre-clinical studies have been conducted to address the various hurdles connected to systemic delivery of reoviruses. The majority of those studies have been done in tumor-bearing immune-deficient murine models. This thwarts studies on the impact of the contribution of the immune system to the tumor cell eradication. This review focuses on key aspects of the reovirus/host-cell interactions and the methods that are available to modify the virus to alter these interactions. These aspects are discussed with a focus on improving the reovirus’ antitumor efficacy. View Full-Text
Keywords: virotherapy; oncolytic viruses; oncolytic cell killing mechanisms; combination therapy; mammalian orthoreoviruses virotherapy; oncolytic viruses; oncolytic cell killing mechanisms; combination therapy; mammalian orthoreoviruses

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kemp, V.; Hoeben, R.C.; van den Wollenberg, D.J.M. Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. Viruses 2016, 8, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top